Peer-reviewed veterinary case report
Survival after surgery with or without chemo for dog spleen cancer
By Batschinski, Karen et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2018·87 - Department of Pathology, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with visceral hemangiosarcoma (a type of cancer affecting blood vessels, often in the spleen) were treated either with surgery alone or surgery followed by a chemotherapy drug called doxorubicin. The dogs that received both treatments lived longer, averaging 274 days, compared to 66 days for those who only had surgery. Dogs with earlier-stage tumors had better survival times, with those at stage I living around 196 days on average. Overall, the average survival time for all dogs in the study was about 179 days, with nearly 30% surviving for a year after treatment.
People also search for: dog hemangiosarcoma treatment · dog cancer surgery survival · doxorubicin for dogs cancer
Abstract
The purpose of this retrospective study was to determine survival times and prognostic factors of dogs with visceral hemangiosarcoma (HSA) treated with surgery alone or surgery and doxorubicin. Medical records from 2 hospitals from 2005 to 2014 were searched for dogs with histopathologically confirmed visceral HSA. Data relevant to patient demographics, tumor characteristics, and outcomes were abstracted. The most common primary organ affected was the spleen; however, primary tumor location had no influence on prognosis. Twenty-three dogs were treated with surgery alone, while 14 dogs were treated with surgery and doxorubicin. There was a significant difference in survival times between dogs treated with surgery alone and with surgery followed by doxorubicin (66 days274 days). Dogs with stage I tumors (196 days) had a longer median survival time (MST) than dogs with stage II (117 days) and stage III (23 days) disease. The overall MST was 179 days with a 1-year survival rate of 29.2%.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30197439/